We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.10 | 1.50 | - | 0.00 | 07:30:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.57 | 1.69M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/12/2020 15:28 | Very unloved is pyc. | albert3591 | |
14/12/2020 09:31 | PYC Physiomics Share Price : 6p Shares o/s : 97m Mkt Cap : £6m Cash : £1m EV : £5m Great RNS which of course won't be appreciated by the AIM herd because it does require some thinking to read between the lines 1. UK Govt funding to partner with NHS to develope an AI/ML precision dosing tool for ONE form of Cancer (Prostate) with ONE drug (docetaxel) 2. This is a demonstrator/validat 3. Physiomics allude to ongoing discussions with an 'Established Player' in the Personalised Medicine field (previously revealed it is a US Company). This would facilitate gaining FDA regulatory approval and targeting huge US commercial opportunity Chart setting up perfectly for a big sustained breakout of this Falling Wedge pattern An EV of £5m is ridiculous for a UK cancer AI/ML company which has UK Govt/NHS backing and could commercialise this technology in the US IF this works across many cancers and many drugs and becomes an across the board Cancer Decision Support System for clinicians the potential value in the $100bn+ p.a. Cancer therapy market is mindblowing | the stigologist | |
11/12/2020 15:22 | SDGR SLP and PYC all strong on $CERT IPO | the stigologist | |
10/12/2020 12:29 | The volume says otherwise. People need to give pyc a break, it's a decent company, creating shard holder value albeit slowly | 7rademark | |
10/12/2020 11:15 | Big technical set up on PYC with 50 and 200 day Moving Average pincer and a low volume pennant ? (similar to March covid move down to 1.7p which saw an April/May snapback to 10p and 17p intraday) | the stigologist | |
10/12/2020 10:52 | Certara $CERT $3bn IPO tomorrow will be hot and bring attention to PYC Certara and Simulations Plus on 15-40x revenue Physiomics valued at just 5x revenue 5 Hot Upcoming IPOs Upcoming IPOs: Certara (CERT) Certara operates a software platform that uses biosimulation to accelerate the discovery and development of drugs. It is essentially a virtual trial, which involves virtual patients. The technology can help answer important questions like: What will the human response be to a drug? How will other drugs interfere with it? What are safe doses? The company is the leader in this emerging space. Over 1,600 biopharma companies and academic institutions have used the system across 60 countries. Note that 17 global regulatory agencies license the software for new drug submissions, such as the FDA and Europe’s EMA. For the first nine months of this year, the revenues reached $179 million, up from $155 million in the same period a year ago. The company also generated $5 million in profits. The ROI (Return On Investment) for Certara can be significant because of the enormous costs of drug development. For example, one customer for Certara saved more than $500 million over a three year period. For the IPO, the company plans to issue 24.4 million shares at a range of $19 to $22. The listing will be on the NASDAQ under the ticker of CERT. The lead underwriters include Jefferies, Morgan Stanley (NYSE:MS), Bank of America (NYSE:BAC), Credit Suisse (NYSE:CS), Barclays (NYSE:BCS) and William Blair. | the stigologist | |
05/12/2020 10:42 | You need to have lots of patients with this one, looking at the charts it looks that it takes one step forward then two steps back until it hit's the 2's then take off! maybe another year+ I'm afraid | sibeks | |
03/12/2020 15:38 | Shoddy any ramping will be done by you,I will buy at 2p WHEN it gets there,perhaps I might say after I have bought 500k that I will sell at 2.85p.wouldn’t want to be greedy. | albert3591 | |
02/12/2020 21:54 | There's nothing to ramp hod. When it drops into the 4s and 3s, buy in, sell at 6. | davevt | |
02/12/2020 20:56 | Before Lower price 1.3 | zxie | |
02/12/2020 19:27 | It’s going to feel weird when dave and albert start ramping this..... I wonder if they’ll be championing the 100p Manifesto? Heheheheh | hodhasharon | |
02/12/2020 14:09 | Bit of a ski slope now girls | albert3591 | |
30/11/2020 15:22 | This is an exciting share is it not. | albert3591 | |
30/11/2020 14:29 | Yes, but no but, Might be summing or nothfin' | officerdigby | |
29/11/2020 14:53 | This little Baby pyc went from 1p to 31p in 72 hours. Could it happen again? No is not an option! | sibeks | |
29/11/2020 14:53 | This little Baby pyc went from 1p to 31p in 72 hours. Could it happen again? No is not an option! | sibeks | |
25/11/2020 21:59 | I am poised to pull the trigger at 4p... and top up/lower my average. I won’t lie and pretend I had already planned to do so at 5p... but I think my new ‘target’ is a fairer representation of the simple facts... Money to be made between 3p and 9p... by the far more astute than my good self... Nothing further to go on than historical swings. Because there’s NOWT going on ‘in house’..!! | maddie275 | |
20/11/2020 10:22 | Why? This share is going exactly where I said it would and you say read a made up post by a ramper on this very board. Listen to the 3p manifesto instead, it's way way way more likely. | davevt | |
19/11/2020 20:50 | Forget cycles, read the 100p Manifesto. | hodhasharon | |
19/11/2020 20:48 | Nope, but it will drop lower...look at today, all sells, then it may be worth buying in.. | davevt | |
19/11/2020 18:45 | Is this one going to burst into action soon? Hate to miss out! | sibeks |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions